Brief: CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
11/03/2026 11:01
March 11 (Reuters) - CRISPR Therapeutics AG CRSP.BN: CRISPR THERAPEUTICS PRICES UPSIZED CONVERTIBLE SENIOR NOTES OFFERING CRISPR THERAPEUTICS AG - PRICES $550 MILLION CONVERTIBLE SENIOR NOTES DUE 2031 CRISPR THERAPEUTICS AG - GRANTS OPTION TO PURCHASE UP TO $50 MILLION ADDITIONAL NOTES Source text: ID:nGNX3Nsxry Further company coverage: CRSP.BN ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crispr Therapeutics AG
See all newsBrief: CRISPR Therapeutics Announces Chief Financial Officer Transition
Swiss stocks - Factors to watch on August 4
Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Swiss stocks - Factors to watch on August 3
Gene-editing firm CRISPR steadies after boosted $550 mln convertible debt deal